The global Necrobiosis Lipoidica Diabeticorum (NLD) market is expected to garner a market value of US$ 4.5 Billion in 2023 and is expected to accumulate a market value of US$ 8.06 Billion by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Necrobiosis Lipoidica Diabeticorum (NLD) registered a CAGR of 4% in the historical period 2017 to 2022.
An increase in the incidence of diabetes, as well as shifts in urbanization and sedentary lifestyle, are important factors driving the Necrobiosis Lipoidica Diabeticorum (NLD) market growth. Furthermore, technological improvements in the field of diabetes, as well as an increase in the diabetic population are propelling the growth.
According to the International Diabetes Federation, Diabetes is becoming more prevalent globally, accounting for 6.7 million deaths by 2021. As a result, Clinical examinations and procedures are carried out to diagnose the condition, which aids medical professionals in making additional decisions about medicine, testing, and recuperation and is expected to accelerate market expansion throughout the projection period.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 4.5 Billion |
| Anticipated Forecast Value (2033) | US$ 8.06 Billion |
| Projected Growth Rate (2023 to 2033) | 6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Necrobiosis Lipoidica Diabeticorum (NLD) reflected a value of 4% during the historical period, 2017 to 2022. Various factors such as awareness in wellness and health, the diagnostics, and pathology segment are improving in developing countries nowadays which grows the therapeutics market. The research and development activities in the field like emerging novel therapeutics, increasing the efficacy of medicine as well as treatment.
Selling campaigns initiated by global players are growing the market progressively. Increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of Necrobiosis Lipoidica Diabeticorum (NLD) is fuelling market growth. Thus, the market for Necrobiosis Lipoidica Diabeticorum (NLD) is expected to register a CAGR of 6% in the forecast period 2023 to 2033.
Strong Relation Between Diabetes & Necrobiosis Lipoidica Diabeticorum (NLD) to push the market growth
The increasing prevalence of Necrobiosis Lipoidica Diabeticorum (NLD) disease is one of the biggest drivers of the market. The massive growth in the diabetic population is primarily attributable to rising NLD rates around the world, as well as sedentary lifestyles defined by poor diets and decreased physical exercise.
According to a study conducted by National Center for Biotechnology Information, Necrobiosis lipoidica diabeticorum (NLD) is a rare chronic and granulomatous skin disorder that affects 0.3% of diabetic patients. The legs are the most common site for NLD, but the involvement of other areas such as the abdomen, upper extremities, and scalp has been reported. There is no rational therapy.
Furthermore, a strong relationship between diabetes and NLD, and many studies have focused on diabetic microangiopathy as the leading etiologic theory. Diabetic alterations of the kidney and eye vasculature are similar to the vascular changes seen in NLD. A deposition of glycoprotein in blood vessel walls may be the cause of diabetic microangiopathy. A similar glycoprotein deposition is seen in NLD. Doppler flow study showed lowered O2 tensions within the lesions.
Considering these in-depth studies, the market is projected to show considerable growth through 2033.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
The expensive treatment of Necrobiosis Lipoidica Diabeticorum (NLD), less awareness of Necrobiosis Lipoidica Diabeticorum (NLD) disease, and insubstantial treatment options are hampering the market growth.
Improvement in healthcare spending propelling the growth of Necrobiosis Lipoidica Diabeticorum (NLD) in Asia Pacific
The Asia Pacific is expected to exhibit a significant growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of Necrobiosis Lipoidica Diabeticorum (NLD) in the region. Asia Pacific is an emerging market due to the increase in point care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the treatment market worldwide.
High prevalence of Skin Infections shaping the landscape for Necrobiosis Lipoidica Diabeticorum (NLD) in North America
North America is anticipated to acquire a market share of about 34% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. As per the ClinicalTrials.gov posted on January 2020, the study titled "Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)" under the clinical development for the drug Dalbavancin from the allergen pharmaceutical in the United States.
Apart from this, An estimated 34.2 million people have diabetes (10.5 percent of the U.S. population). Therefore, the risk of Necrobiosis Lipoidica Diabeticorum (NLD) rises in the region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Hospitals to take the lead and drive market growth
The application segment has been divided into hospitals, retail pharmacies, and Ambulatory Surgical Centres. According to the FMI analysis, Hospitals account for the largest market share. The requirement for several hospital stays and visits during NLD treatment facilitates the growth of this segment.
Key start-up players in the Necrobiosis Lipoidica Diabeticorum (NLD) market are-
Key players in the Necrobiosis Lipoidica Diabeticorum (NLD) market are ALexicare Pharma, Andréas Astier, Mayo Clinic, AbbVie Inc, Merck & Co., Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., Pfizer, Novartis AG, and GlaxoSmithKline Plc.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 4.5 Billion |
| Market Value in 2033 | US$ 8.06 Billion |
| Growth Rate | CAGR of 6% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled | Lexicare Pharma, Andréas Astier, Mayo Clinic, AbbVie Inc, Merck & Co., Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., Pfizer, Novartis AG, GlaxoSmithKline Plc. |
| Customization | Available Upon Request |
From 2017 to 2022, the Necrobiosis Lipoidica Diabeticorum (NLD) market grew at a CAGR of 4%.
The global Necrobiosis Lipoidica Diabeticorum (NLD) market is expected to grow with a 6% CAGR from 2023 to 2033.
As of 2033, the Necrobiosis Lipoidica Diabeticorum (NLD) market is expected to reach US$ 8.06 Billion
According to the FMI analysis, hospitals account for the largest market share.
North America is expected to possess 34% market share for the Necrobiosis Lipoidica Diabeticorum (NLD) market.
The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.
1. Executive Summary | Necrobiosis Lipoidica Diabeticorum Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Procedure
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Procedure, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Procedure, 2023 to 2033
5.3.1. Treatment
5.3.1.1. Corticosteroid Creams
5.3.1.2. Injected Corticosteroids
5.3.1.3. Drugs that Suppress the Immune System
5.3.1.4. Anti-inflammatory Drugs
5.3.1.5. Medicines that Improve Blood Flow
5.3.1.6. Hyperbaric Oxygen Therapy
5.3.1.7. Phototherapy
5.3.1.8. Laser Therapy
5.3.2. Test Type
5.3.2.1. Punch Biopsy
5.3.2.2. Glucose Tolerance Test
5.4. Y-o-Y Growth Trend Analysis By Procedure, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Procedure, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033
6.3.1. Hospitals
6.3.2. Ambulatory Surgical Centres
6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East & Africa (MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. The US
8.2.1.2. Canada
8.2.2. By Procedure
8.2.3. By Application
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Procedure
8.3.3. By Application
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Procedure
9.2.3. By Application
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Procedure
9.3.3. By Application
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. The UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Procedure
10.2.3. By Application
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Procedure
10.3.3. By Application
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Procedure
11.2.3. By Application
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Procedure
11.3.3. By Application
11.4. Key Takeaways
12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Procedure
12.2.3. By Application
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Procedure
12.3.3. By Application
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. The US
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Procedure
13.1.2.2. By Application
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Procedure
13.2.2.2. By Application
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Procedure
13.3.2.2. By Application
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Procedure
13.4.2.2. By Application
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Procedure
13.5.2.2. By Application
13.6. The UK
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Procedure
13.6.2.2. By Application
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Procedure
13.7.2.2. By Application
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Procedure
13.8.2.2. By Application
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Procedure
13.9.2.2. By Application
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Procedure
13.10.2.2. By Application
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Procedure
13.11.2.2. By Application
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Procedure
13.12.2.2. By Application
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Procedure
13.13.2.2. By Application
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Procedure
13.14.2.2. By Application
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Procedure
13.15.2.2. By Application
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Procedure
13.16.2.2. By Application
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Procedure
13.17.2.2. By Application
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Procedure
13.18.2.2. By Application
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Procedure
13.19.2.2. By Application
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Procedure
13.20.2.2. By Application
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Procedure
14.3.3. By Application
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Lexicare Pharma
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Andréas Astier
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Mayo Clinic
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. AbbVie Inc
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Merck & Co., Inc.
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Bristol-Myers Squibb Company
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Johnson & Johnson Services Inc.
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Pfizer
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Novartis AG
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. GlaxoSmithKline Plc.
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Explore Healthcare Insights
View Reports
Necrobiosis Lipoidica Diabeticorum Market
